As a follow up to ProtoKinetix Inc.’s May 23, 2007 press release related to cryopreserved (or frozen) cells treated with AAGP™, in collaboration with the University of Helsinki, Finland, ProtoKinetix has recently finished a set of trials designed to determine whether AAGP™ treated cells could survive after preservation in refrigeration (4°C).
Commenting on the results, ProtoKinetix’s Director of Scientific Affairs, Dr. John Todd, stated, “After 3 days of preservation in refrigeration, untreated stem cells have a very high mortality rate. In the most recent experiments with the University of Helsinki, Finland, it was determined that AAGP™ can significantly reduce this cell death rate. AAGP™ demonstrated an impressive and repetitive 8 to 12 times increase in cell viability and survivability.”
Dr. Todd added, “These results are extremely important and encouraging for isolating the limited stem cell populations found in certain organs and tissues, such as umbilical cord blood and bone marrow. The implications for the treatment of certain types of cancers, such as leukemia and other conditions requiring bone marrow transplant are enormous.”